Eli Lilly announced Wednesday that it had acquired CoLucid Pharmaceuticals for $960M in an all-cash transaction, regaining ownership of lasmiditan, a late-stage migraine drug that could be commercialized as early as 2018.
What do Johnson & Johnson, FedEx and Verizon Communications have in common? Aside from being Fortune 500 companies, they’re also led by former members of the U.S. military. According to a new Kauffman Foundation study just released, veterans aren’t starting businesses like they used to, but they are definitely leading them. It makes sense, really, […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Central nervous system drug development company CoLucid is currently in talks with potential partners who could take its investigational migraine headache treatment into late-stage clinical trials. The company offered no details on the prospective drug partners, but said it does now have the U.S. Food and Drug Administration’s go-ahead to proceed with phase 3 trials. […]
Central nervous system disorders pharmaceutical company CoLucid has named a new CEO who takes over a firm that is making progress on what is expected to be a breakthrough migraine headache treatment. Thomas Mathers takes the reins at Durham, North Carolina-based CoLucid as the company looks to phase 3 clinical trials on its lead drug […]